In the case of the Breast Cancer dataset, our approach shows a superior performance to the pre-operative treatment response (pCR, pathologic complete response) endpoint, but an inferior performance to the estrogen receptor (ER) endpoint, Figure 4. This evidence concerns the gene ESR1 and breast cancer.